Clinical importance of cytokine (IL-6, IL-8, and IL-10) and vitamin D levels among patients with Type-1 diabetes

Azharuddin Sajid Syed Khaja; Naif K. Binsaleh; MIrza Masroor Ali Beg; Fauzia Ashfaq; Mohammad Idreesh Khan; Malak Ghazi Almutairi; Husam Qanash; Mohd Saleem; Ibrahim Abdelmageed Mohamed Ginawi

doi:10.1038/s41598-024-73737-6

journal article Open Access Oct 16, 2024

Clinical importance of cytokine (IL-6, IL-8, and IL-10) and vitamin D levels among patients with Type-1 diabetes

Azharuddin Sajid Syed Khaja Naif K. Binsaleh MIrza Masroor Ali Beg Fauzia Ashfaq

Mohammad Idreesh Khan

Malak Ghazi Almutairi Husam Qanash

Mohd Saleem Ibrahim Abdelmageed Mohamed Ginawi

Scientific Reports Vol. 14 No. 1 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/s41598-024-73737-6

Topics

No keywords indexed for this article. Browse by subject →

References

59

[1]

Willcox, A. & Gillespie, K. M. Histology of type 1 diabetes pancreas. Methods Mol. Biol. 1433, 105–117 (2016). 10.1007/7651_2015_287

[2]

2022, I. A. R. Type 1 Diabetes Estimates in Children and Adults (International Diabetes Federation, 2022).

[3]

Jahromi, M. & Al-Ozairi, E. Human Leukocyte Antigen (HLA) and islet autoantibodies are tools to characterize type 1 diabetes in arab countries: emphasis on Kuwait. Dis. Markers 2019, 9786078 (2019). 10.1155/2019/9786078

[4]

Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study

Gabriel A Gregory, Thomas I G Robinson, Sarah E Linklater et al.

The Lancet Diabetes & Endocrinology 2022 10.1016/s2213-8587(22)00218-2

[5]

Global estimates of incidence of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Atlas, 10th edition

Graham D. Ogle, Steven James, Dana Dabelea et al.

Diabetes Research and Clinical Practice 10.1016/j.diabres.2021.109083

[6]

DiMeglio, L. A., Evans-Molina, C. & Oram, R. A. Type 1 diabetes. Lancet 391(10138), 2449–2462 (2018). 10.1016/s0140-6736(18)31320-5

[7]

Eizirik, D. L., Colli, M. L. & Ortis, F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat. Rev. Endocrinol. 5(4), 219–226 (2009). 10.1038/nrendo.2009.21

[8]

Pankewycz, O. G., Guan, J. X. & Benedict, J. F. Cytokines as mediators of autoimmune diabetes and diabetic complications. Endocr. Rev. 16(2), 164–176 (1995). 10.1210/edrv-16-2-164

[9]

Singh, B., Nikoopour, E., Huszarik, K., Elliott, J. F. & Jevnikar, A. M. Immunomodulation and regeneration of islet Beta cells by cytokines in autoimmune type 1 diabetes. J. Interferon Cytokine Res. 31(10), 711–719 (2011). 10.1089/jir.2011.0025

[10]

Jones, S. A. & Jenkins, B. J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 18(12), 773–789 (2018). 10.1038/s41577-018-0066-7

[11]

Ahmadi, Z., Arababadi, M. K. & Hassanshahi, G. CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus. Inflammation 36(2), 364–371 (2013). 10.1007/s10753-012-9555-1

[12]

Ismail, N. A. et al. Monocyte chemoattractant protein 1 and macrophage migration inhibitory factor in children with type 1 diabetes. J. Pediatr. Endocrinol. Metab. 29(6), 641–645 (2016). 10.1515/jpem-2015-0340

[13]

Harsunen, M. H. et al. Reduced blood leukocyte and neutrophil numbers in the pathogenesis of type 1 diabetes. Horm. Metab. Res. 45(6), 467–470 (2013). 10.1055/s-0032-1331226

[14]

Ouyang, W. & O’Garra, A. IL-10 family cytokines IL-10 and IL-22: from Basic Science to Clinical Translation. Immunity 50(4), 871–891 (2019). 10.1016/j.immuni.2019.03.020

[15]

Hotta-Iwamura, C. & Tarbell, K. V. Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment. J. Leukoc. Biol. 100(1), 65–80 (2016). 10.1189/jlb.3mr1115-500r

[16]

Kleffel, S. et al. Interleukin-10 + regulatory B cells arise within antigen-experienced CD40 + B cells to maintain tolerance to islet autoantigens. Diabetes 64(1), 158–171 (2015). 10.2337/db13-1639

[17]

Forouhi, N. G., Luan, J., Cooper, A., Boucher, B. J. & Wareham, N. J. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely prospective study 1990–2000. Diabetes 57(10), 2619–2625 (2008). 10.2337/db08-0593

[18]

Labudzyns’kyi, D. O., Shymans’kyi, I. O., Riasnyi, V. M. & Velykyi, M. M. Vitamin D3 availability and functional activity of peripheral blood phagocytes in experimental type 1 diabetes. Ukr. Biochem. J. 86(2), 107–118 (2014). 10.15407/ubj86.02.107

[19]

Rak, K. & Bronkowska, M. Immunomodulatory Effect of Vitamin D and its potential role in the Prevention and Treatment of Type 1 diabetes Mellitus-A Narrative Review. Molecules 24(1). (2018). 10.3390/molecules24010053

[20]

Neal, S., Sykes, J., Rigby, M. & Hess, B. A review and clinical summary of vitamin D in regard to bone health and athletic performance. Phys. Sportsmed. 43(2), 161–168 (2015). 10.1080/00913847.2015.1020248

[21]

Holick, M. F. et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(7), 1911–1930 (2011). 10.1210/jc.2011-0385

[22]

Tolonen, N. et al. Different lipid variables predict incident coronary artery disease in patients with type 1 diabetes with or without diabetic nephropathy: the FinnDiane study. Diabetes Care 37(8), 2374–2382 (2014). 10.2337/dc13-2873

[23]

Vaisar, T. et al. High concentration of medium-sized HDL particles and Enrichment in HDL Paraoxonase 1 associate with Protection from Vascular complications in People with Long-standing type 1 diabetes. Diabetes Care 43(1), 178–186 (2020). 10.2337/dc19-0772

[24]

Bebu, I. et al. Mediation of the Effect of Glycemia on the risk of CVD outcomes in type 1 diabetes: the DCCT/EDIC study. Diabetes Care 42(7), 1284–1289 (2019). 10.2337/dc18-1613

[25]

Abed, E. et al. Prevalence of dyslipidemia and factors affecting dyslipidemia in young adults with type 1 diabetes: evaluation of statin prescribing. J. Pediatr. Endocrinol. Metab. 32(4), 327–334 (2019). 10.1515/jpem-2018-0383

[26]

Bojanin, D. et al. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: effects of glycemic control. Atherosclerosis 280, 14–20 (2019). 10.1016/j.atherosclerosis.2018.11.020

[27]

Warraich, H. J. & Rana, J. S. Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and implications of newer therapies. Curr. Cardiol. Rep. 20(12), 125 (2018). 10.1007/s11886-018-1068-6

[28]

Kantoosh, M. M., Naiem, A. M., El-Sayad, M. & Nashat, M. Dyslipidemia and lipid peroxidation in type 1 diabetic children with good glycemic control: response to antioxidant therapy. Alex J. Pediatr. 16, 357–364 (2002).

[29]

Patiakas, S. et al. The lipid profile of patients with diabetes mellitus in Paionia County. Diabetol. und Stoffwechsel 2, 04 (2007). 10.1055/s-2007-984781

[30]

Alrabaty, A. A., Alnakshabandi, A. A. & Yahya, N. B. The lipid profile in children with type 1 diabetes mellitus in Erbil governorate. Iraqi Postgrad. Med. J. 8, 344–349 (2009).

[31]

Mona, H. M., Sahar, S. A., Hend, S. M. & Nanees, A-W-A. Dyslipidemia in type 1 diabetes mellitus: relation to diabetes duration, glycemic control, body habitus, dietary intake and other epidemiological risk factors. Egypt. Pediatr. Association Gaz. 63(2), 63–68 (2015). 10.1016/j.epag.2015.03.001

[32]

Rojas-Martínez, R. et al. Prevalence of obesity and metabolic syndrome components in Mexican adults without type 2 diabetes or hypertension. Salud pública de méxico 54(1), 7–12 (2012).

[33]

Donath, M. Y., Dinarello, C. A. & Mandrup-Poulsen, T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nat. Rev. Immunol. 19(12), 734–746 (2019). 10.1038/s41577-019-0213-9

[34]

Campbell-Thompson, M. et al. Insulitis and beta-cell Mass in the natural history of type 1 diabetes. Diabetes 65(3), 719–731 (2016). 10.2337/db15-0779

[35]

Pugliese, A. Autoreactive T cells in type 1 diabetes. J. Clin. Invest. 127(8), 2881–2891 (2017). 10.1172/jci94549

[36]

Bender, C., Rajendran, S. & von Herrath, M. G. New insights into the role of autoreactive CD8 T cells and cytokines in human type 1 diabetes. Front. Endocrinol. (Lausanne) 11, 606434 (2020). 10.3389/fendo.2020.606434

[37]

Snell-Bergeon, J. K. et al. Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study. J. Clin. Endocrinol. Metab. 95(6), 2868–2876 (2010). 10.1210/jc.2009-1993

[38]

Alnek, K. et al. Increased blood levels of growth factors, Proinflammatory cytokines, and Th17 cytokines in patients with newly diagnosed type 1 diabetes. PLoS One 10(12), e0142976 (2015). 10.1371/journal.pone.0142976

[39]

Yin, Y. W. et al. The lack of association between interleukin-6 gene – 174 G/C polymorphism and the risk of type 1 diabetes mellitus: a meta-analysis of 18,152 subjects. Gene 515(2), 461–465 (2013). 10.1016/j.gene.2012.11.062

[40]

Campbell, I. L., Hobbs, M. V., Dockter, J., Oldstone, M. B. & Allison, J. Islet inflammation and hyperplasia induced by the pancreatic islet-specific overexpression of interleukin-6 in transgenic mice. Am. J. Pathol. 145(1), 157–166 (1994).

[41]

Hundhausen, C. et al. Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. Sci. Transl. Med. 8(356), 356ra119 (2016). 10.1126/scitranslmed.aad9943

[42]

Schloot, N. C. et al. Association of immune mediators at diagnosis of type 1 diabetes with later clinical remission. Diabet. Med. 24(5), 512–520 (2007). 10.1111/j.1464-5491.2007.02096.x

[43]

Siewko, K. et al. Interleukin-6 and Interleukin-15 as possible biomarkers of the risk of Autoimmune Diabetes Development. Biomed. Res. Int. 2019, 4734063 (2019). 10.1155/2019/4734063

[44]

Nomura, S., Shouzu, A., Omoto, S., Nishikawa, M. & Fukuhara, S. Significance of chemokines and activated platelets in patients with diabetes. Clin. Exp. Immunol. 121(3), 437–443 (2000). 10.1046/j.1365-2249.2000.01324.x

[45]

Dakovic, D. et al. Salivary interleukin-8 levels in children suffering from type 1 diabetes mellitus. J. Clin. Pediatr. Dent. 37(4), 377–380 (2013). 10.17796/jcpd.37.4.l135531h4542gj66

[46]

Erbagci, A. B., Tarakcioglu, M., Coskun, Y., Sivasli, E. & Sibel Namiduru, E. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin. Biochem. 34(8), 645–650 (2001). 10.1016/s0009-9120(01)00275-2

[47]

Foss-Freitas, M. C., Foss, N. T., Donadi, E. A. & Foss, M. C. Effect of the glycemic control on intracellular cytokine production from peripheral blood mononuclear cells of type 1 and type 2 diabetic patients. Diabetes Res. Clin. Pract. 82(3), 329–334 (2008). 10.1016/j.diabres.2008.09.003

[48]

Jain, S. K., Rains, J. L. & Croad, J. L. High glucose and ketosis (acetoacetate) increases, and chromium niacinate decreases, IL-6, IL-8, and MCP-1 secretion and oxidative stress in U937 monocytes. Antioxid. Redox Signal. 9(10), 1581–1590 (2007). 10.1089/ars.2007.1577

[49]

Nunes, R. Cordova CMMd. Th1 and Th2 response cytokins in type 1 diabetes Mellitus. Revista Brasileira De Análises Clínicas 49(4). (2017). 10.21877/2448-3877.201700596

[50]

Bruun, J. M., Pedersen, S. B. & Richelsen, B. Interleukin-8 production in human adipose tissue. Inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin. Horm. Metab. Res. 32(11–12), 537–541 (2000). 10.1055/s-2007-978682

Showing 50 of 59 references

Metrics

22

Citations

59

References

Details

Published: Oct 16, 2024
Vol/Issue: 14(1)
License: View

Authors

A

Azharuddin Sajid Syed Khaja

N

Naif K. Binsaleh

M

MIrza Masroor Ali Beg

F

Fauzia Ashfaq

Department of Clinical Nutrition, College of Applied Medical Sciences, Jazan University, Jazan 45142, Saudi Arabia

M

Mohammad Idreesh Khan

Department of Clinical Nutrition, College of Applied Health Sciences in Arras, Qassim University, Buraydah 58883, Saudi Arabia

M

Malak Ghazi Almutairi

Ibrahim Abdelmageed Mohamed Ginawi

Funding

Scientific Research Deanship at the University of Ha’il Award: MDR-22 024

Cite This Article

Azharuddin Sajid Syed Khaja, Naif K. Binsaleh, MIrza Masroor Ali Beg, et al. (2024). Clinical importance of cytokine (IL-6, IL-8, and IL-10) and vitamin D levels among patients with Type-1 diabetes. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-73737-6

Clinical importance of cytokine (IL-6, IL-8, and IL-10) and vitamin D levels among patients with Type-1 diabetes

You May Also Like